MEK inhibition suppresses K-Ras wild-type cholangiocarcinoma in vitro and in vivo via inhibiting cell proliferation and modulating tumor microenvironment

PD901, a MEK inhibitor, has been demonstrated of therapeutic efficacy against cholangiocarcinoma (CCA) harboring K-Ras oncogenic mutations. However, most CCA exhibit no K-Ras mutations. In the current study, we investigated the therapeutic potential of PD901, either alone or in combination with the...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Pan, Song, Xinhua, Utpatel, Kirsten, Shang, Runze, Yang, Yoon Mee, Xu, Meng, Zhang, Jie, Che, Li, Gordan, John, Cigliano, Antonio, Seki, Ekihiro, Evert, Matthias, Calvisi, Diego F., Hu, Xiaosong, Chen, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370758/
https://www.ncbi.nlm.nih.gov/pubmed/30741922
http://dx.doi.org/10.1038/s41419-019-1389-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370758/
https://www.ncbi.nlm.nih.gov/pubmed/30741922
http://dx.doi.org/10.1038/s41419-019-1389-4

Ejemplares similares